Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 16,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Terminated Phase 1 Interventional

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
BBI-940, Fulvestrant
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NCT00019435
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel in Node Positive Adjuvant Breast Cancer

NCT00688740
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, 5-fluorouracil, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions
INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Drug · Biological
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 29, 2026, 4:37 AM EDT
Terminated Not applicable Interventional

Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy

NCT01821768
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sentinel Lymph Node Biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 29, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

NCT01984268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ACTHAR
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Placebo, secukinumab (AIN457), etanercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Microdermabrasion for Acne

NCT00355485
View directory record Official record
Conditions
Acne Vulgaris
Interventions
microdermabrasion
Device
Lead sponsor
University of Michigan
Other
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 29, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

NCT01585415
View directory record Official record
Conditions
Metastatic Cancer, Melanoma
Interventions
Vemurafenib, Young TIL, Cyclophosphamide, Fludarabine, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer

NCT01290835
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic radiotherapy delivered by CyberKnife, stereotactic radiotherapy
Radiation
Lead sponsor
Essentia Health
Other
Eligibility
60 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional

Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars

NCT00469235
View directory record Official record
Conditions
Keloid
Interventions
Avotermin
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Oct 29, 2026, 4:37 AM EDT
Not listed Phase 2 Interventional

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

NCT02939274
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Verteporfin, Continuous Low-Irradiance Photodynamic Therapy (CLIPT)
Drug · Device
Lead sponsor
Rogers Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

NCT00721435
View directory record Official record
Conditions
Breast Cancer, Mass Cystic, Benign Mass
Interventions
3D Tomosynthesis and ultrasound imaging
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 29, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

NCT07362017
View directory record Official record
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Interventions
Ponesimod
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Glendale, Arizona • Fremont, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 29, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)

NCT01588717
View directory record Official record
Conditions
Hyperhydrosis, Depression
Interventions
Glycopyrrolate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 3 Interventional

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

NCT00000985
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Vidarabine, Acyclovir, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Investigate Contemplative Intervention in Lupus Patients

NCT03103243
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Mindfulness Based Group Sessions
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

NCT02324608
View directory record Official record
Conditions
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
cetuximab, laboratory biomarker analysis
Biological · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 29, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

NCT07116876
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Lower Extremity
Interventions
Graft Application, Wound Dressing Material
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Castro Valley, California • Fresno, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional

A Treatment Study of Mucopolysaccharidosis Type IIIB

NCT02754076
View directory record Official record
Conditions
MPS III B, Mucopolysaccharidosis Type IIIB
Interventions
AX 250
Drug
Lead sponsor
Allievex Corporation
Industry
Eligibility
1 Year to 10 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 29, 2026, 4:37 AM EDT